CoChat

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

The DOI matches its Crossref record; 23 of the 26 references it cites were found in a registry or an index.

Abstract

Background Treatments that confer survival benefit are needed in patients with heavily pretreated metastatic colorectal cancer. The aim of this trial was to investigate the efficacy and safety of TAS-102-a novel oral nucleoside antitumour agent. Methods Between August 25, 2009, and April 12, 2010, we undertook a multicentre, double-blind, randomised, placebo-controlled phase 2 trial in Japan. Eligible patients were 20 years or older; had confirmed colorectal adenocarcinoma; had a treatment history of two or more regimens of standard chemotherapy; and were refractory or intolerant to fluoropyrimidine, irinotecan, and oxaliplatin. Patients had to be able to take oral drugs; have measurable lesions; have an Eastern Cooperative Oncology Group performance status of between 0 and 2; and have adequate bone-marrow, hepatic, and renal functions within 7 days of enrolment. Patients were randomly assigned (2:1) to either TAS-102 (35 mg/m(2) given orally twice a day in a 28-day cycle [2-week cycle of 5 days of treatment followed by a 2-day rest period, and then a 14-day rest period]) or placebo; all patients received best supportive care. Randomisation was done with minimisation methods, with performance status as the allocation factor. The randomisation sequence was generated with a validated computer system by an independent team from the trial sponsor. Investigators, patients, data analysts, and the trial sponsor were masked to treatment assignment. The primary endpoint was overall su…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(12)70345-5

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 330

Metadata

Authors
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., Tsuji, Y., Moriwaki, T., Esaki, T., Hamada, C., Tanase, T., & Ohtsu, A.
Affiliations
  • National Cancer Center Hospital East (JP)
  • The Cancer Institute Hospital (JP)
  • Shizuoka Cancer Center (JP)
  • Shikoku Cancer Center (JP)
  • Hokkaido University Hospital (JP)
  • Kumamoto University Hospital (JP)
  • Kochi Health Sciences Center (JP)
  • Saitama Cancer Center (JP)
  • Aichi Cancer Center Hospital (JP)
  • Osaka International Cancer Institute (JP)
  • Tonan Hospital (JP)
  • University of Tsukuba (JP)
  • National Hospital Organization Kyushu Cancer Center (JP)
  • Tokyo University of Science (JP)
  • Taiho Pharmaceutical (Japan) (JP)
Corresponding author
Yoshino, Takayuki
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2012-10
Volume
13
Issue
10
Pages
993-1001
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2141434947
Cited by
326
References
26
Citations by year
2026: 12 · 2025: 17 · 2024: 17 · 2023: 21 · 2022: 14 · 2021: 30 · 2020: 34 · 2019: 21 · 2018: 28 · 2017: 32 · 2016: 32 · 2015: 39 · 2014: 16 · 2013: 8 · 2012: 4
FWCI
10.76
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Taiho Pharmaceutical
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
trifluridine/tipiracil, S-1, metastatic colorectal cancer, oral chemotherapy, second-line therapy, heavily pretreated patients, overall survival, best supportive care, drug safety, adverse events
MeSH terms
Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Proto-Oncogene Proteins, Pyrrolidines, Thymine, Trifluridine, Uracil, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ras Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(12)70345-5
The paper
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., Tsuji, Y., Moriwaki, T., Esaki, T., Hamada, C., Tanase, T., & Ohtsu, A. (2012). TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(12)70345-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.